Fennec beats, 78% YoY revenue growth, positive EBITDA, signals accelerating 2H26 momentum

 

Fennec beats Q2 2026 estimates with 78% YoY revenue growth, positive EBITDA, signals accelerating 2H26 momentum

• Non-GAAP EPS was $0.02 in Q2 2026, up 118% YoY and beating analyst estimates.
• Q2 2026 revenue was $16.2M, up 68% YoY and ahead of expectations.
• Q2 net product sales reached $17.1M, up 78% YoY on strong demand.
• Non-GAAP adjusted EBITDA turned positive to $2.8M, from $1.2M loss prior-year.
• Expanded sales force drove 280% more calls and record patient enrollments and infusions.
• July showed all-time highs for infusions, enrollments, active patients, and new customers.
• Medical affairs expanded HCP reach 63% and affiliated sites 72%, supporting broader adoption.
• Company reiterates 2026 cash operating expense guidance of ~$50M, with $20–22M 2H spend.
• Cash increased to $41.2M; management expects year-end cash higher despite Q3 dip.
• Pipeline expansion via investigator-sponsored trials may support label expansion and guideline upgrades.
• International opportunity in Japan progressing; partnering discussions ongoing, timing and structure still uncertain.
• Key risk remains single-product dependence on PEDMARK and need for sustained prescription momentum.
• Main concern: Single-product concentration and execution risk around guideline upgrades, label expansion, and Japan partnering.
• Strong quarter, driven by accelerating PEDMARK uptake and improving profitability with positive EBITDA and cash.

https://finviz.com/stock?t=FENC&p=d